Overview

A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer

Status:
Unknown status

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

This open label, randomised, stratified, 2-arm, multicentre, phase 2 trial aims to determine the activity and safety of Lu-PSMA vs cabazitaxel in men with progressive metastatic castration resistant prostate cancer

Phase:

Phase 2

Details

Lead Sponsor:

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Collaborators:

Australasian Radiopharmaceutical Trials network (ARTnet)
Australian Nuclear Science and Technology Organisation (ANSTO)
Endocyte
Movember Foundation
Prostate Cancer Foundation of Australia (PCFA)

Treatments:

177Lu-PSMA-617